ZNHIT6

Across TCGA pan-cancer cohorts, ZNHIT6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNHIT6 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ZNHIT6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZNHIT6 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, LUAD, and PDAC are the cancer types where ZNHIT6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.498	0.210	.009	8	view →
LUAD	DFS	Quartile	All	1.000	0.916	.003	7	view →
PDAC	OS	Quartile	III,IV	0.855	0.198	.010	6	view →
HNSC	OS	Median	All	0.994	0.942	.037	6	view →
LSCC	DFS	Tertile	All	0.884	0.368	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNHIT6–GBM (OS)

Open the GBM breakdown →